Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment
- PMID: 33632927
- PMCID: PMC8127352
- DOI: 10.1158/1078-0432.CCR-20-4009
Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment
Abstract
Purpose: While evidence indicates that Fusobacterium nucleatum (F. nucleatum) may promote colorectal carcinogenesis through its suppressive effect on T-cell-mediated antitumor immunity, the specific T-cell subsets involved remain uncertain.
Experimental design: We measured F. nucleatum DNA within tumor tissue by quantitative PCR on 933 cases (including 128 F. nucleatum-positive cases) among 4,465 incident colorectal carcinoma cases in two prospective cohorts. Multiplex immunofluorescence combined with digital image analysis and machine learning algorithms for CD3, CD4, CD8, CD45RO (PTPRC isoform), and FOXP3 measured various T-cell subsets. We leveraged data on Bifidobacterium, microsatellite instability (MSI), tumor whole-exome sequencing, and M1/M2-type tumor-associated macrophages [TAM; by CD68, CD86, IRF5, MAF, and MRC1 (CD206) multimarker assay]. Using the 4,465 cancer cases and inverse probability weighting method to control for selection bias due to tissue availability, multivariable-adjusted logistic regression analysis assessed the association between F. nucleatum and T-cell subsets.
Results: The amount of F. nucleatum was inversely associated with tumor stromal CD3+ lymphocytes [multivariable OR, 0.47; 95% confidence interval (CI), 0.28-0.79, for F. nucleatum-high vs. -negative category; P trend = 0.0004] and specifically stromal CD3+CD4+CD45RO+ cells (corresponding multivariable OR, 0.52; 95% CI, 0.32-0.85; P trend = 0.003). These relationships did not substantially differ by MSI status, neoantigen load, or exome-wide tumor mutational burden. F. nucleatum was not significantly associated with tumor intraepithelial T cells or with M1 or M2 TAMs.
Conclusions: The amount of tissue F. nucleatum is associated with lower density of stromal memory helper T cells. Our findings provide evidence for the interactive pathogenic roles of microbiota and specific immune cells.
©2021 American Association for Cancer Research.
Figures

References
-
- El Bairi K, Jabi R, Trapani D, Boutallaka H, Ouled Amar Bencheikh B, Bouziane M, et al. Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. Expert Rev Clin Pharmacol 2020;13(4):403–21 doi 10.1080/17512433.2020.1758063. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R35 CA197735/CA/NCI NIH HHS/United States
- R01 CA118553/CA/NCI NIH HHS/United States
- C10674/A27140/CRUK_/Cancer Research UK/United Kingdom
- P01 CA087969/CA/NCI NIH HHS/United States
- R01 CA248857/CA/NCI NIH HHS/United States
- P50 CA101942/CA/NCI NIH HHS/United States
- R37 CA225655/CA/NCI NIH HHS/United States
- U01 CA167552/CA/NCI NIH HHS/United States
- R01 CA137178/CA/NCI NIH HHS/United States
- K24 DK098311/DK/NIDDK NIH HHS/United States
- R01 CA205406/CA/NCI NIH HHS/United States
- R01 CA169141/CA/NCI NIH HHS/United States
- R35 CA253185/CA/NCI NIH HHS/United States
- P50 CA127003/CA/NCI NIH HHS/United States
- K07 CA190673/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 CA151993/CA/NCI NIH HHS/United States
- 27140/CRUK_/Cancer Research UK/United Kingdom
- UM1 CA186107/CA/NCI NIH HHS/United States
- K07 CA188126/CA/NCI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical